Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1589 - Identification of new prognostic factors in phase I patients treated by immunotherapy

Date

10 Oct 2016

Session

Poster display

Presenters

Frédéric Bigot

Citation

Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368

Authors

F. Bigot1, E. Castanon Alvarez1, A. Hollebecque1, A. Carmona2, S. Postel-Vinay1, E. Angevin1, J. Armand1, V. Ribrag1, S. Aspeslagh1, A. Varga1, R. Bahleda1, A. Gazzah1, C. Bonnet1, J. Michot1, A. Marabelle1, J. Soria1, C. Massard1

Author affiliations

  • 1 Department Of Medicine Ditep, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Medical Oncology, Hospital Universitario Morales Meseguer, Murcia/ES
More

Resources

Abstract 1589

Background

Evaluation of patient's life expectancy is crucial to select patient who may benefit from phase I studies. The Royal Marsden Hospital score (RMH) established a prognostic tool validated in prospective studies and based on 3 objectives variables: number of metastatic sites, LDH and serum albumin. Nevertheless, it remains unclear if those factors could be extended to immunotherapy phase I trials.

Methods

A retrospective analysis of risk factors of early death for patients enrolled into immune checkpoint inhibitor phase I trials in our institution was conducted. Demographic and biological characteristics (age, gender, number of metastatic site, LDH, albumin, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count) were analyzed with univariate and multivariable analysis for overall survival.

Results

155 patients (Male: 83; Median age was 59 (22-88)) treated with an experimental immunotherapy between March 2012 and January 2016 were analyzed. The most frequent tumor types were non-small cell lung cancer (16.7%), head and neck cancer (12.2%), urothelial cancer (10.3%), renal cancer (9%), breast cancer (7.7 %), cervical cancer (6.4%). In the multivariable model, Albumin (HR: 1.7; 95%CI 1.06-2.9) and LDH (HR: 1.9; 95%CI 1.2-3.2) remained statistical significant; nevertheless the number of metastases had no impact on the patients treated with immunotherapy (HR: 0.8; 95%CI 0.5-1.3). Interestingly, a higher neutrophil-to-lymphocyte ratio (NLR) was associated with a worse prognosis (HR = 1.8; 95%CI 1.1-3). We generated a new score with albumin (upper normal limit = +1) and NLR (>6 =+ 1). We performed a Harrell c-index for evaluating the suitability of this new score (c index = 0.70; 95%CI 0.64-0.77) which was slightly higher than the c-index for RMH score in our series (0.65; 95% CI 0.58-0.72).

Conclusions

Our study points that the addition of NLR to classical prognostic variables such as albumin and LDH, may predict better the overall survival of patients that are treated with immunotherapy. The number of metastasis has no prognostic value in our series. Although this score needs an external validation, this is a valuable tool to make a better selection of patients for phase 1 immunotherapy trials.

Clinical trial identification

Legal entity responsible for the study

Christophe Massard

Funding

Institut Gustave Roussy

Disclosure

J-C. Soria: Personal fees AstraZeneca, Astex, Covagen, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings